NCT03928353View on ClinicalTrials.gov

Study to Evaluate the Safety, Tolerability, PK and PD of PB2452 in Healthy Younger, Older and Elderly Subjects

PHASE2CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

April 16, 2019

Primary Completion Date

October 9, 2019

Study Completion Date

October 9, 2019

Conditions
Healthy
Interventions
DRUG

PB2452 Infusion

30 minute - 24 hour infusion

DRUG

Placebo - Sodium Chloride

30 minute - 24 hour infusion

DRUG

Ticagrelor Oral Tablet - Pre-Treatment

Ticagrelor 180 mg + 90 mg BID for 5 doses prior to PB2452 or Placebo

DRUG

Ticagrelor Oral Tablet - Pre-Treatment and Post-Treatment

Ticagrelor 180 mg + 90 mg BID for 5 doses prior to PB2452 or Placebo and Ticagrelor 180 mg 24 hours following PB2452 or Placebo

DRUG

Ticagrelor Oral Tablet - Pre-Treatment

Ticagrelor 180 mg BID for 5 doses prior to PB2452 or Placebo

DRUG

PB2452 Infusion

30 minute - 16 hour infusion

DRUG

Placebo - Sodium Chloride

Placebo - Sodium Chloride

Trial Locations (1)

78744

PPD, Austin

All Listed Sponsors
lead

SFJ Pharmaceuticals, Inc.

INDUSTRY

NCT03928353 - Study to Evaluate the Safety, Tolerability, PK and PD of PB2452 in Healthy Younger, Older and Elderly Subjects | Biotech Hunter | Biotech Hunter